https://www.selleckchem.com/pr....oducts/nedometinib.h
The clinical impact of invasive hemodynamic support with Impella in patients with cardiogenic shock (CS) remains to be defined. Only studies including patients treated with Impella in CS were selected. The primary endpoint was short term mortality, while secondary endpoints were major vascular complications and major bleeding. 17 studies and 3933 patients were included in the analysis. Median age was 61.9 (IQR 59.2-63.5) years, CS was mainly related to acute coronary syndrome (ACS) 79.6% (IQR 75.1-79.6). Thirty-day mortality was 47.
إعجاب
علق
شارك
